<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="156312">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01805492</url>
  </required_header>
  <id_info>
    <org_study_id>WRI-03-03</org_study_id>
    <secondary_id>MDA W81XWH-05-2-0075</secondary_id>
    <nct_id>NCT01805492</nct_id>
  </id_info>
  <brief_title>Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal</brief_title>
  <official_title>Global Profiling of Gene and Protein Expression Associated With Coronary Heart Disease Reversal</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Windber Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Windber Research Institute</source>
  <oversight_info>
    <authority>United States: Institutional Review Board</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to characterize changes in gene and protein expression in
      peripheral blood in patients with, or at risk for, heart disease during an intensive
      lifestyle modification program.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This project will use an integrated approach that examines DNA variation and the functional
      products of genes at both the messenger RNA (mRNA) and protein levels to provide a global
      view of molecular changes associated with drastic lifestyle modifications designed to
      reverse coronary heart disease (CHD). DNA variants and/or changes in gene and protein
      expression associated with CHD reversal may provide important clues to understanding
      molecular mechanisms of subclinical CHD development and progression.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2000</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">February 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Change in body mass index</measure>
    <time_frame>Baseline, 12 weeks, 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in BMI from baseline to 12 weeks and from baseline to 52 weeks</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in blood pressure</measure>
    <time_frame>Baseline, 12 weeks, 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in BP from baseline to 12 weeks and from baseline to 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in lipids</measure>
    <time_frame>Baseline, 12 weeks, 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in HDL-, LDL-, total cholesterol, and triglycerides from baseline to 12 weeks and from baseline to 52 weeks</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in exercise capacity</measure>
    <time_frame>Baseline, 12 weeks, 52 weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Change in exercise capacity from baseline to 12 weeks and from baseline to 52 weeks</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">422</enrollment>
  <condition>Heart Diseases</condition>
  <condition>Cardiovascular Diseases</condition>
  <arm_group>
    <arm_group_label>Intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dr. Dean Ornish Program for Reversing Heart Disease</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Non-intervention controls retrospectively matched to intervention participants</description>
  </arm_group>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>Dr. Dean Ornish Program for Reversing Heart Disease</intervention_name>
    <description>Prospective, nonrandomized clinical intervention to stabilize or reverse progression of heart disease through changes in lifestyle. Lifestyle intervention consisted of four components: 1) a very low fat vegetarian diet (&lt;10% of calories from fat); 2) 180 minutes/week of moderate aerobic exercise; 3) one hour of stress management each day; and 4) weekly group support sessions.</description>
    <arm_group_label>Intervention</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  diagnosis of coronary artery disease (CAD)

          -  stable angina

          -  angioplasty

          -  evidence of &gt;50% luminal narrowing on coronary angiogram

          -  acute myocardial infarction

          -  bypass surgery

          -  stent placement OR

          -  two or more CAD risk factors

          -  systolic pressure &gt;140 mm Hg or diastolic pressure &gt;90 mm Hg)

          -  high total cholesterol (&gt;200 mg/dL)

          -  physician diagnosed diabetes

          -  body mass index (BMI) &gt;30

          -  family history of heart disease in parents or siblings

          -  21 years of age or older

          -  mentally competent to provide informed consent

        Exclusion Criteria:

          -  known history of autoimmune disease

          -  systemic/chronic disease requiring chemotherapy or long term treatment
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Darrell L Ellsworth, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Windber Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Windber Medical Center</name>
      <address>
        <city>Windber</city>
        <state>Pennsylvania</state>
        <zip>15963</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.wriwindber.org/</url>
    <description>Windber Research Institute home page</description>
  </link>
  <results_reference>
    <citation>Ellsworth DL, O'Dowd SC, Salami B, Hochberg A, Vernalis MN, Marshall D, Morris JA, Somiari RI. Intensive lifestyle modification: impact on cardiovascular disease risk factors in subjects with and without clinical cardiovascular disease. Prev Cardiol. 2004 Fall;7(4):168-75.</citation>
    <PMID>15539963</PMID>
  </results_reference>
  <results_reference>
    <citation>Vizza J, Neatrour DM, Felton PM, Ellsworth DL. Improvement in psychosocial functioning during an intensive cardiovascular lifestyle modification program. J Cardiopulm Rehabil Prev. 2007 Nov-Dec;27(6):376-83; quiz 384-5. doi: 10.1097/01.HCR.0000300264.07764.84.</citation>
    <PMID>18197071</PMID>
  </results_reference>
  <results_reference>
    <citation>Decewicz DJ, Neatrour DM, Burke A, Haberkorn MJ, Patney HL, Vernalis MN, Ellsworth DL. Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy. Lipids Health Dis. 2009 Jun 29;8:26. doi: 10.1186/1476-511X-8-26.</citation>
    <PMID>19563671</PMID>
  </results_reference>
  <results_reference>
    <citation>Voeghtly LM, Neatrour DM, Decewicz DJ, Burke A, Haberkorn MJ, Lechak F, Patney HL, Vernalis MN, Ellsworth DL. Cardiometabolic risk reduction in an intensive cardiovascular health program. Nutr Metab Cardiovasc Dis. 2012 May 25. [Epub ahead of print]</citation>
    <PMID>22633795</PMID>
  </results_reference>
  <verification_date>March 2013</verification_date>
  <lastchanged_date>March 4, 2013</lastchanged_date>
  <firstreceived_date>February 21, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Windber Research Institute</investigator_affiliation>
    <investigator_full_name>Darrell L Ellsworth</investigator_full_name>
    <investigator_title>Senior Director, Integrative Cardiac Health Program</investigator_title>
  </responsible_party>
  <keyword>Heart diseases</keyword>
  <keyword>Cardiovascular diseases</keyword>
  <keyword>Lifestyle modification</keyword>
  <keyword>Diet</keyword>
  <keyword>Exercise</keyword>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Cardiovascular Diseases</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
    <mesh_term>Heart Diseases</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
